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Abstract
Background During the end-of-life (EOL) phase of glioma pa-
tients, a rapid deterioration in neurological functioning may in-
terfere with the oral intake of antiepileptic drugs (AEDs). We
aimed to assess the feasibility of non-oral AED treatment in an
out-of-hospital setting according to an expert-based guideline.
Methods Glioma patients with a history of epilepsy, in whom
further antitumor therapy was considered to be no longer
meaningful, were recruited at two Dutch hospitals. As soon
as swallowing difficulties developed, the patient’s caregiver
administered prophylactic treatment with buccal clonazepam.
Acute seizures were treated with intranasal midazolam. We
evaluated the adherence to the study medication, seizure prev-
alence, and caregiver’s satisfaction.
Results Of the 34 patients who were approached, 25 gave
consent to participate and 23 had died at the end of the study.
Thirteen of 19 patients (68.4 %) who had developed
swallowing difficulties showed adherence to the study proto-
col. Thirteen patients used prophylactic buccal clonazepam, of
which eight patients remained seizure-free until death. Six
patients received treatment with intranasal midazolam at least
once. In all patients, seizure control was reached. None of the
patients needed to be transferred to the hospital due to recur-
rent seizures. All caregivers were to some degree satisfied
with the use of the study medication.
Conclusions Our results demonstrate that it is feasible to treat
seizures with a combination of non-oral benzodiazepines in
the EOL phase of glioma patients, as it seems to provide an
important level of comfort among caregivers to be able to
manage seizures at home.
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Introduction
Seizures are a relatively common symptom in patients with a
glioma, occurring in 30–90 % of patients, depending on the
glioma subtype [1, 2]. Recent studies have shown that seizures
persist during the end stage of the disease in many glioma
patients, with reported prevalence during the end-of-life
(EOL) phase ranging from 21 to 52 % [3–5]. Patients who
have a history of epilepsy are particularly prone to suffer from
seizures in the EOL phase, but de novo seizures in the EOL
phase have also been reported [3, 6].
During the EOL phase, care is primarily aimed at re-
ducing symptom burden and maintaining quality of life.
However, a rapid deterioration in neurological and cogni-
tive functioning may interfere with the oral intake of med-
ication during the EOL phase [7]. Swallowing difficulties
are seen in up to 85 % of patients who are in the terminal
phase of a malignant brain tumor [8]. Moreover, almost
all brain tumor patients demonstrate progressive confu-
sion or coma in the last days before death [9, 10]. Thus,
EOL symptoms may eventually hamper the administration
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of oral antiepileptic drugs (AEDs) [6]. To prevent inade-
quate AED treatment shortly before death, alternative
AED treatment regimens are needed.
To overcome the difficulties in treating seizures during
the EOL phase, our group has developed a guideline on
the use of alternative administration routes of AEDs in
glioma patients suffering from epilepsy that can easily
be applied at home by patient’s informal caregivers. In
this guideline, we propose to start non-oral AED treat-
ment with buccal clonazepam and intranasal midazolam
as soon as the intake of oral AEDs is no longer possible
[11, 12]. Buccal clonazepam has the advantage of a long
elimination half-life and can safely be applied as a pro-
phylactic treatment in the out-of-hospital setting [13–15].
In the acute treatment of seizures, intranasal midazolam
has shown a similar efficacy and safety in comparison
with intravenous or rectal diazepam [16, 17]. Moreover,
caregivers appear to prefer the use of intranasal midazo-
lam [12, 18].
In the current study, we aim to assess the feasibility of a
treatment protocol with the combination of buccal clonaze-
pam and intranasal midazolam in the EOL phase of glioma
patients according to an expert-based guideline. We evaluat-
ed the adherence to the study medication, caregiver’s satis-
faction, as well as seizure prevalence before and after initi-
ation of the medication.
Methods
Patients
Adult patients (≥18 years) with a histologically confirmed
glioma (World Health Organization (WHO) grade II or III
astrocytoma, oligodendroglioma, or oligoastrocytoma or
WHO grade IV glioblastoma) in whom further antitumor
therapy was considered to be no longer meaningful were
eligible for inclusion. All patients had a history of at least
one seizure during the course of their disease and received
treatment with oral AEDs at study entry. An informal care-
giver needed to be prepared to apply the treatment protocol
at home. Patients with any known history of sensitivity to
benzodiazepines or with a percutaneous endoscopic
gastrostomy tube were excluded from the study. We consid-
ered all patients for participation who received routine
follow-up at two tertiary referral centers for brain tumor
patients in The Netherlands: one large community hospital
(Medical Center Haaglanden, The Hague) and one universi-
ty hospital (VU University Medical Center, Amsterdam).
The study received approval from the Institutional Review
Board (IRB) of both hospitals. All patients and caregivers
provided written, informed consent.
Study design
We recruited patients at the outpatient clinic in both hospitals
between May 2012 and November 2014. In case the patient
decided to participate, the clinical nurse specialist instructed
the patient and informal caregiver on the details of the proto-
col. We informed the patient’s general practitioner on the pa-
tient’s participation by letter. Patients who fulfilled the in- and
exclusion criteria but declined to participate were recorded
separately.
As soon as a patient was included in the study, the clinical
nurse specialist contacted the patient and/or informal caregiver
on a weekly basis and asked for the ability to use the regular
oral AEDs. We instructed the patient or caregiver to continue
the regular oral AED treatment as long as possible. We asked
them to contact the nurse specialist in case swallowing diffi-
culties were developing that hampered the regular oral intake
of AEDs.
The treatment guideline was formed in 2011 during meet-
ings at the VUmc with experts from different disciplines:
neuro-oncology, pharmacology, epilepsy, and palliative med-
icine. Their main goal was to prepare a guideline to treat
epilepsy in the EOL phase of brain tumor patients that could
easily be applied by patient’s caregivers in an out-of-hospital
setting. After discussing possible non-oral AEDs that could be
administered during the EOL phase, a combination of prophy-
lactic treatment with buccal clonazepam and emergency treat-
ment with intranasal midazolam was regarded as the most
appropriate AED treatment regimen.
The content of the guideline was as follows: when the
administration of oral AEDs was no longer possible, the care-
giver started to administer prophylactic treatment with buccal
clonazepamwith an initial dose of two–four times 0.5 mg/day,
followed by a maintenance dose of four times 0.5–1.0 mg/day.
In case of recurrent seizures, the daily dose was gradually
increased in steps of 1–2 mg/day until seizures were con-
trolled, intolerable adverse effects occurred, or the maximum
maintenance dose of 20 mg/day had been reached. Dose ad-
justments were made after consultation of the nurse specialist
or treating physician. Clinically visible seizures were treated
with one puff of intranasal midazolam in each nostril (total of
5 mg midazolam). If seizures persisted for 5 min despite the
administration of intranasal midazolam, a second dose of 5 mg
was administered. We instructed the caregiver to contact the
hospital or general practitioner in case a second dose of mid-
azolam failed as well. We considered the emergency treatment
successful in case seizures were suppressed for at least 2 h
after administration of the last dose.
The nurse specialist stayed in contact with the caregiver at
least once a week as soon as the study medication (buccal
clonazepam and/or intranasal midazolam) was started, to col-
lect data on seizure prevalence, use of the studymedication, its
efficacy, and possible adverse effects. In case of recurrent
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seizures, the nurse specialist contacted the caregiver on a daily
basis until seizure control was effected. We derived additional
information on various aspects of the EOL phase from a short
questionnaire, completed by the caregivers after patient’s
death. The questionnaire included questions on the patient’s
general condition during the EOL phase; reasons for non-
administration of the study medication; adverse drug effects;
as well as three questions on caregiver’s satisfaction with (1)
explanation of the treatment protocol, (2) the administration of
buccal clonazepam, and (3) the administration of intranasal
midazolam.We collected data on demographics, tumor histol-
ogy, seizure type, and seizure frequency before the EOL phase
from the hospital medical charts.
Study end points
The primary end point of the pilot study was adherence to the
treatment protocol, determined by the number of patients that
were treated according to the study protocol until death. The
treatment protocol was deemed feasible if at least 50 % of the
included patients in whom oral AED treatment was no longer
possible were treated according to the guideline. The second-
ary end points were caregiver’s satisfaction with the study
medication (according to a 7-point Likert scale ranging from
(1) completely dissatisfied to (7) completely satisfied), seizure
prevalence after initiation of the study medication, adverse




Of the 34 patients who were approached, 25 patients gave
consent to participate (Fig. 1). At the end of the study, 23
out of 25 patients (92.0 %) had died. The median duration
from time of consent to time of death was 3.2 months for these
23 patients (range 0.3–7.2 months). Four of 23 patients
(17.4 %) were able to use their oral AEDs until death. Twenty
of 23 caregivers (response rate 87.0 %) completed the ques-
tionnaire on the EOL phase with a median interval of
7.5 months (range 1–20 months) after patient’s death.
A summary of baseline data of all patients is outlined in
Table 1 (for details per patient, see supplementary Table 1).
Seventeen of 23 patients (73.9 %) were male with a mean age
of 56.7 years. Nineteen of 23 patients (82.6 %) died at home.
Twelve of 23 patients (52.2 %) had a history of generalized
seizures, 7 patients (30.4 %) of simple partial seizures, 3
(13.0 %) of a combination of partial and generalized seizures,
and 1 patient (4.3%) of complex partial seizures. Fifteen of 23
patients (65.2 %) had a seizure frequency of <1 seizure/month
before the start EOL phase, the other 8 patients (37.5 %) re-
ported higher frequencies.
Treatment
Fourteen of 19 patients (73.7 %) used either buccal clonaze-













9 paents excluded due to:
- quick deterioraon in symptoms (5)
- unwillingness to parcipate (2)
- hospital admission (1)
- language barrier (1)
6 paents did not start study medicaon due to:
- use of other non-oral AEDs (3)
- paent used midazolam, refused clonazepam (1)
- complete refusal of administraon (1)
- unknown reason (1)
2 paents sll 
alive at end of 
study
4 paents able to 
use oral AEDs 
unl death
Fig. 1 Inclusion of subjects
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these 14 patients only received intranasal midazolam, as he
refused the administration of buccal clonazepam. So eventu-
ally, 13 of 19 patients (68.4%; 95%CI 47.1–89.7%)who had
developed swallowing difficulties completely adhered to the
study protocol. In the remaining 6/19 patients (35.2 %), the
study medication was not administered for various reasons
(Fig. 1). One of these six patients who did not receive the
study medication according to the treatment protocol reported
seizures during the last week before death. In all 14 patients
who used any study medication, the caregiver completed a
questionnaire on the EOL phase. Treatment characteristics
per patient are outlined in supplementary Table 2.
Thirteen patients used buccal clonazepam as prophylactic
treatment. After the start of buccal clonazepam, 8 of 13 pa-
tients (61.5 %) remained seizure free. The other five patients
reported seizures after the start of clonazepam, which all oc-
curred during the last week before death. In 2 of 13 patients
(15.4 %), a dose increase was necessary due to recurrent sei-
zures. In the remaining 3 of 13 patients (23.1 %), a dose
increase was not necessary, as seizure control was achieved
after emergency treatment with intranasal midazolam. Treat-
ment with buccal clonazepamwas started during the last week
before death in 9 of 13 patients (69.2 %).
Six patients received treatment with intranasal midazolam
at least once. In these 6 patients, a total of 16 seizures were
treated, and only in 1 of these 16 seizures a second dose was
necessary to achieve seizure control. One of the six patients
who received intranasal midazolam refused prophylactic treat-
ment with buccal clonazepam. In all six patients who were
treated with intranasal midazolam, seizure control could be
reached.
None of the patients needed to be transferred to the hospital
due to recurrent seizures. In one patient, the general practition-
er decided to replace buccal clonazepam by subcutaneous
Table 1 Baseline characteristics
N (%)
Gender Male 17 (73.9)
Female 6 (26.1)
Mean age, years (SD) 56.7 (8.5)
Tumor grade Glioblastoma 13 (56.5)
Anaplastic glioma 6 (26.1)
Low-grade glioma 4 (17.4)
Primary caregiver Partner 22 (95.7)
Professional caregiver 1 (4.3)
Seizure type Generalized 12 (52.2)
Simple partial 7 (30.4)
Complex partial 1 (4.3)
Both partial and generalized 3 (13.0)
Seizure frequency before EOL phase <1/month 15 (65.2)
>1/month 6 (26.1)
>1/week 2 (8.7)
KPS at 1 week before death, mean (range) 30 (20–50)
Place of death Home 19 (82.6)
Hospice 3 (13.0)
Care hotel 1 (4.3)
Adherence to study protocol Yes 13 (56.5)
No 6 (26.1)
Use of oral AEDs until death 4 (17.4)
Use of buccal clonazepam (n=19) Yes 13 (68.4)
No 6 (31.6)





Use of intranasal midazolam (n=19) Yes 6 (31.6)
No 13 (68.4)
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midazolam 3 days before death due to seizure recurrence.
Adverse effects of the study medication were scarce. In one
patient, a dry mouth was reported after start of the study med-
ication. In none of the patients intolerable adverse effects were
reported that led to discontinuation of treatment or that with-
held the physician from increasing the clonazepam mainte-
nance dose.
Caregiver’s satisfaction
Of all 20 caregivers who completed the questionnaire on the
EOL phase, 19 caregivers (95.0 %) had the opinion that they
had received clear instructions by the nurse specialist on the
use of the study medication. None of the 13 caregivers who
had administered buccal clonazepam were dissatisfied with
the use of the medication. Six of 13 caregivers (46.2 %) were
mostly or completely satisfied with its use (6 or 7 on a 7-point
Likert scale) and 7 of 13 (53.8 %) were neutral or somewhat
satisfied (4 or 5 out of 7). Of the six caregivers who had
administered intranasal midazolam, all were mostly or
completely satisfied with its use.
Discussion
The primary objective of this study was to assess the feasibil-
ity of a non-oral AED treatment protocol in the EOL phase of
glioma patients. According to our predefined criteria, it ap-
pears to be feasible to administer AED treatment with buccal
clonazepam and intranasal midazolam shortly before death, as
approximately two thirds of patients who had developed
swallowing difficulties showed adherence to the study medi-
cation regimen.Moreover, we found that all caregivers were at
least to some extent satisfied with the administration of buccal
clonazepam or intranasal midazolam.
This is the first study in which the feasibility of non-oral
AED treatment has been prospectively examined in the EOL
phase of glioma patients. Our results confirm the high preva-
lence of dysphagia and loss of consciousness that underlie
swallowing difficulties in the EOL phase [9]. In line with
previous retrospective studies, we found that only 17 % of
patients were able to use their regular oral AEDs until death
[3]. To date, no information has been available on the time at
which EOL symptoms start to hamper oral drug administra-
tion in glioma patients. Our study reveals that swallowing
difficulties become burdensome at a relatively late stage of
the disease. In 69 % of patients who used the study medica-
tion, swallowing difficulties did not develop until the last
week before death.
Almost all participating caregivers showed satisfaction
with the use of the non-oral AED treatment, particularly re-
garding the emergency treatment with intranasal midazolam.
In patients with refractory non-tumor-related epilepsy,
caregiver’s satisfaction with the use of nasal spray has also
been demonstrated [18]. The absence of any transfers to the
hospital due to uncontrolled seizures as well as the lack of
serious side effects may have contributed to the caregiver’s
satisfaction. In addition, in only 6 % of cases the caregiver or
patient refused participation in the study. The clear willingness
to participate seems to reflect an urgent need to prevent seizure
recurrence in the EOL phase. As it is known that caregivers
particularly fear seizures shortly before death, they probably
find it reassuring to be able to manage the seizures when
necessary [19].
Altogether, 26 % of patients who were included in the
study reported at least one seizure during the last week
before death. These findings correspond to previous series
that showed seizure prevalence between 28 and 38 % dur-
ing the last week [6, 8, 20]. However, we were unable to
determine the true efficacy of the study medication given
the absence of an appropriate control group in our study.
Other limitations of the study include the relatively small
sample size and the high dependence on inexperienced
caregivers who had a central role in administering the
medication, observing its effect, as well as reporting in-
formation to the nurse specialist. Furthermore, adverse
drug effects were rarely reported and may have gone un-
noticed due to the patient’s rapidly declining condition. In
addition, the role of prophylactic treatment in patients
without a history of seizures is still unknown.
Despite the fact that five patients still experienced
seizures after treatment with prophylactic buccal clonaz-
epam had been started, seizure freedom or at least tem-
porary seizure control could eventually be achieved in
all patients. However, a randomized controlled study is
required to know whether the study medication leads to
a reduction in seizures during the EOL phase. It is
noteworthy that none of the participating patients need-
ed rehospitalization due to refractory seizures. A previ-
ous study demonstrated that avoiding transitions be-
tween health care settings is of major importance in
glioma patients and may eventually contribute to a more
dignified death [21].
In conclusion, the results of this study demonstrate that it is
feasible to treat seizures in the EOL phase according to a
treatment protocol with a combination of non-oral benzodiaz-
epines. It seems to provide an important level of comfort
among caregivers to be able to manage seizures in an out-of-
hospital setting. As the risk of seizures persists until death,
AED treatment should be easily accessible to all glioma pa-
tients in the EOL phase who have a history of epilepsy, par-
ticularly when EOL symptoms start to interfere with their oral
AED intake.
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